Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Eric Sprott Announces Changes to His Holdings in Honey Badger Silver Inc. (click to learn more) This micro-cap stock is leading the US graphite revolution (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Rein Therapeutics Inc RNTX

Healthcare Biotechnology
As of August 3, 2005, HSS RentX was acquired by Sunbelt Rentals, Inc. HSS RentX owns and operates a network of rental stores that offer professional tools, equipment, and special event rental products. The company specializes in material handling and lifting gear hire equipment for the construction industry, removal companies, and general industry, as well as operates a fleet of platform and... see more

Recent & Breaking News (NDAQ:RNTX)

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

GlobeNewswire April 30, 2026

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

GlobeNewswire April 29, 2026

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

GlobeNewswire March 3, 2026

Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

GlobeNewswire January 20, 2026

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

GlobeNewswire November 6, 2025

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

GlobeNewswire November 3, 2025

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

GlobeNewswire October 9, 2025

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

GlobeNewswire September 17, 2025

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

GlobeNewswire August 19, 2025

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

GlobeNewswire August 14, 2025

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

GlobeNewswire July 30, 2025

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

PR Newswire June 24, 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

PR Newswire May 27, 2025

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

PR Newswire May 19, 2025

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

PR Newswire May 15, 2025

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

PR Newswire May 12, 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

PR Newswire May 1, 2025

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

PR Newswire April 30, 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

PR Newswire April 28, 2025

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

PR Newswire April 23, 2025

Podcasts